|
J&J Subsidiary Cites Quickening Pace of Doxil Production; Janssen Tops Off Cancer Trial
Janssen Products has indicated that supplies of its shorted ovarian cancer drug Doxil may return to the market faster than previously thought.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives